trending Market Intelligence /marketintelligence/en/news-insights/trending/Buc9he6C3c-HEDM45SuaQA2 content esgSubNav
In This List

Ziopharm Oncology names president

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Ziopharm Oncology names president

ZIOPHARM Oncology Inc. said David Mauney has been promoted to president, effective Dec. 13.

Mauney joined the company in 2017 as executive vice president and chief business officer. Previously, Mauney served as managing director at Harvest Capital Strategies LLC.

Boston-based Ziopharm Oncology is a biotechnology company that focuses on acquiring, developing and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.